21.1 billion yuan domestic market of lipid regulating drugs, 80% of which

In the future, blood lipid regulating drugs will still be the mainstream products of cardiovascular and cerebrovascular drugs Among them, "statins" are commonly used clinical drugs, accounting for 84.4% of the total lipid regulating drugs in 2016 According to the guideline for prevention and treatment of dyslipidemia in Chinese adults (2016 Revision), the overall prevalence of dyslipidemia in Chinese adults is as high as 40.4% The increase of serum cholesterol level will lead to an increase of 9.2 million cardiovascular events in China from 2010 to 2030 The results of the national survey in 2012 showed that the prevalence of hypercholesterolemia was 4.9%; the prevalence of hypertriglyceridemia (TG) was 13.1%; and the prevalence of low-density lipoprotein cholesterol (HDL-C) was 33.9%   none="shifuMouseDownPayStyle('shifu_t_052')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; width: 20em; text-align: center; box-sizing: border-box !im portant; Word wrap: break word! Im portant; "> at present, there are HMG CoA reductase inhibitors, shellfish, niacin and its derivatives, cholic acid chelating agents, cholesterol absorption inhibition, antioxidant and polyene fatty acids, PCSK9 inhibition agents, which are common drugs for regulating blood lipids According to the data monitoring of Zhongkang CMH, the overall market of lipid regulating drugs showed an upward trend from 2013 to 2016, with the sales volume reaching 21.165 billion yuan in 2016, an increase of 14.2% over 2015 The compound growth rate in 2013-2016 was 14.6% With the acceleration of the aging of China's social population, the deepening of hierarchical diagnosis and treatment reform, the promotion of Medical Association and family doctor system, and the increasingly sound management of chronic diseases of the elderly, it is expected that the market of lipid regulating drugs in China will maintain a good growth momentum in the next five years Figure 1 data source of market sales of lipid regulating drugs in China from 2013 to 2016: Zhongkang CMH According to the data monitoring of Zhongkang CMH, the main sales channels of lipid regulating drugs were in grade hospitals from 2013 to 2016, which accounted for 64.7%, 22.9% and 12.3% respectively With the continuous promotion of national medical reform and the establishment of hierarchical diagnosis and treatment system, the grass-roots market has been gradually strengthened In 2016, the proportion of lipid regulating drugs in the grass-roots level was 12.3%, up 1.8% compared with 2015 It is expected that the grassroots market will continue to expand in the future Figure 2 data source of sales channels of lipid regulating drugs in 2013-2016: according to the monitoring data of Zhongkang CMH, the lipid regulating drugs in 2013-2016 are mainly chemical drugs, accounting for 91.94% in 2016, while the proportion of proprietary Chinese medicine and biological medicine is relatively low, and shrinking year by year However, with the listing of PCSK9 inhibitors in China, the proportion of biopharmaceuticals will gradually expand in the future Figure 3 proportion of lipid regulating drugs in 2013-2016 data source: Zhongkang CMH According to the monitoring of Zhongkang CMH data, the market of lipid regulating drugs in 2013-2016 is dominated by HMG CoA reductase inhibitors, i.e "statins" are still the mainstream products of treatment drugs in this field Other antilipidemic drugs mainly include some Chinese patent medicines, and the market is shrinking year by year The market growth rate of cholesterol absorbents is good Figure 4 Data source of the proportion of each subclass of lipid regulating drugs in 2013-2016: according to the monitoring of the data of Zhongkang CMH, the sales channels of each subclass of lipid regulating drugs in 2016 were more in the grade hospitals, and cholic acid chelating agents were mainly sold in the retail channels The overall channel situation is consistent with the sales channel situation of this category Figure 5 Data source of channel proportion of lipid regulating drugs in 2016: according to the data monitoring of Zhongkang CMH, the top 10 products of lipid regulating drugs in 2016 are mainly statins, and the top 10 drugs account for 91.8% of the total market share in 2016, with high market concentration Among them, the market growth of rosuvastatin, pravastatin and compound amlodipine atorvastatin is fast As a Chinese patent medicine, zhizhikang accounted for 2.8% of the total sales in 2016 Table 1 market situation of top 10 generic names of blood lipid drugs in 2016 (10000 yuan) data source: Zhongkang CMH Table 2 generic names of blood lipid drugs (10000 yuan) data source: Zhongkang CMH none = "shifumousedownpaystyle ('shifu_t_ ')" style = "margin: 1em Auto; padding: 0px; max width: 100%; color: rgb (62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; width: 20em; text-align: center; box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> PCSK9 inhibitor, the most noteworthy lipid regulating drug, has a powerful effect on reducing blood lipid On the basis of statins treatment, it can reduce cholesterol level in the body by more than 50% PCSK9 inhibitor can accelerate the removal of cholesterol in the body by reducing the degradation of LDL-R on the surface of liver cells Different from the mechanism of statins in inhibiting cholesterol synthesis and reducing the "way", PCSK9 inhibitor is the "way" to increase cholesterol By reducing the degradation of LDL-R, it can stabilize the amount of LDL-R and accelerate the removal of synthesized cholesterol in the body In the future, PCSK9 inhibitors will occupy a large market share in lipid regulating products In 2015, praluent (alirocumab), an all human monoclonal antibody product of Sanofi and its partner regeneron pharmaceutical company in the United States, was approved by FDA, and repatha (evolocumab) of Amgen was approved by EU Pfizer's bococizumab is expected to receive a third approval Lilly, Bristol Myers Squibb, Merck, Novartis and other drugs targeting PCSK9 targets are all in clinical research With the expiration of patents for statins (rosuvastatin expires in 2016, atorvastatin expires in 2011), PCSK9 inhibitor will be the fastest-growing new blood lipid regulating drug after statins In 2015, repatha of Amgen has started phase III clinical trials in China The research and development of PCSK9 inhibitors in China is also being actively carried out Junshi and XinDa biology are in the forefront of domestic PCSK9 research.